Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia
NCT ID: NCT00417326
Last Updated: 2012-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
174 participants
INTERVENTIONAL
2006-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan
NCT00219375
Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
NCT05962606
Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia
NCT04459676
Study for Novel Coronavirus Pneumonia (NCP)
NCT04283396
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
NCT05123755
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
P
ONO-5046Na
twenty four hour infusion at 0 mg/kg/hr for 14 days
E
ONO-5046Na
twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ONO-5046Na
twenty four hour infusion at 0 mg/kg/hr for 14 days
ONO-5046Na
twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with acute respiratory failure
Exclusion Criteria
* Patients on mechanical ventilation
20 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ono Pharmaceutical Co. Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Koji Takehara
Role: STUDY_DIRECTOR
Ono Pharmaceutical Co. Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chugoku Region
Chugoku, , Japan
Chubu Region
Chūbu, , Japan
Hokkaido Region
Hokkaido, , Japan
Hokuriku Region
Hokuriku, , Japan
Kanto Region
Kanto, , Japan
Kinki Region
Kinki, , Japan
Kyushu Region
Kyushu, , Japan
Shikoku Region
Shikoku, , Japan
Tohoku Region
Tohuku, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ONO-5046Na-14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.